ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 102.80% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 95.30%, a 4.82% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 94.04%, a 7.81% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 91.11%, a 5.39% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-09-30 was 90.92%, a 6.02% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 102.80%, a 2.88% increase from fiscal 2024.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 99.92%, a 14.85% increase from fiscal 2023.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 87.00%, a 2.59% increase from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 84.80%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | 102.80% 10-K · filed 2026-03-10 | ||||||
| 2025-09-30 | 102.60% 10-Q · filed 2025-11-12 | ||||||
| 2024-12-31 | 99.92% 10-K · filed 2026-03-10 | 91.99% 10-K · filed 2025-03-06 | |||||
| 2024-09-30 | 95.30% 10-Q · filed 2024-11-07 | 99.92% 10-Q · filed 2025-11-12 | 91.99% 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | 94.04% 10-Q · filed 2025-07-24 | 91.32% 10-Q · filed 2025-07-24 | |||||
| 2024-03-31 | 91.11% 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | 87.00% 10-K · filed 2025-03-06 | ||||||
| 2023-09-30 | 90.92% 10-Q · filed 2024-11-07 | 86.55% 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 87.23% 10-Q · filed 2024-08-08 | 86.55% 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | 86.45% 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | 84.80% 10-K · filed 2024-03-12 | ||||||
| 2022-09-30 | 85.76% 10-Q · filed 2023-11-09 | 84.68% 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 83.55% 10-Q · filed 2023-08-10 | 0.85% 10-Q · filed 2022-08-11 | 84.41% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 83.55% 10-Q · filed 2023-05-15 | ||||||
| 2021-06-30 | 72.50% 10-Q · filed 2021-08-12 | ||||||
| 2021-03-31 | 72.65% 10-Q · filed 2022-05-12 | ||||||
| 2020-06-30 | 73.90% 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |